Breast cancer
Conditions
Interventions
single-arm group:Solvent-based paclitaxel or paclitaxel injection (albumin-bound)combined with HP
Sponsors
Maoming People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. HER2-positive Stage II-III locally advanced breast cancer confirmed by pathological examination, who have not received any anti-tumor therapy before; 2. hormone receptor status is known; 3. Female, aged 18 to 70 years; 4. LVEF>=55%; 5. The ECOG score was 0 or 1, and follow-up treatment was assessed; they volunteered to join the study, signed informed consent, had good compliance and were willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating female patients, female patients with fertility and a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial; 2. Patients with severe cardiovascular and cerebrovascular or mental related diseases; 3. Those who have used research drugs in other clinical trials 4 weeks before enrollment; 4. Patients with bilateral breast cancer and inflammatory breast cancer; 5. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study (including but not limited to severe hypertension that cannot be controlled by drugs, severe diabetes, etc.); the investigator believes that the patient is not suitable to participate in this study. any other circumstances of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;Pathological complete remission rate of breast tumor;3-year invasion-free survival; | — |
Countries
China
Contacts
Public ContactShen Meiying
Maoming People's Hospital
Outcome results
None listed